[1] 中华医学会肝病学分会.肝硬化诊治指南.中华肝脏病杂志,2019,27:846-865.
[2] Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension: the pulmonary vascular enigmas of liver disease. Clin Liver Dis (Hoboken), 2020,15:S13-13S24.
[3] Krowka MJ, Fallon MB, Kawut SM, et al. International Liver Transplant Society Practice Guidelines: Diagnosis and Management of Hepatopulmonary Syndrome and Portopulmonary Hypertension. Transplantation, 2016,100:1440-1452.
[4] 杨苏乔, 杨媛华, 邝土光, 等. 门脉高压性肺动脉高压临床特点及靶向药物治疗分析. 中华医学杂志, 2019,99:2806-2810.
[5] DuBrock HM, Krowka MJ. The Myths and realities of portopulmonary hypertension. Hepatology, 2020,72:1455-1460.
[6] DuBrock HM, Rodriguez-Lopez JM, LeVarge BL, et al. Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension. Pulm Circ, 2016,6:498-507.
[7] Nikolic I, Yung LM, Yang P, et al. Bone morphogenetic protein 9 is a mechanistic biomarker of portopulmonary hypertension. Am J Respir Crit Care Med, 2019,199:891-902.
[8] Raevens S, Colle I, Reyntjens K, et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: an analysis of cutoff values. Liver Transpl, 2013,19:602-610.
[9] Thévenot T, Savale L, Sitbon O. Portopulmonary hypertension: an unfolding story. Clin Res Hepatol Gastroenterol, 2021,45:101492.
[10] AbuHalimeh B, Krowka MJ, Tonelli AR. Treatment barriers in portopulmonary hypertension. Hepatology, 2019,69:431-443.
[11] Sitbon O, Bosch J, Cottreel E, et al. Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. Lancet Respir Med, 2019,7:594-604.
[12] Preston IR, Burger CD, Bartolome S, et al. Ambrisentan in portopulmonary hypertension: a multicenter, open-label trial. J Heart Lung Transplant, 2020,39:464-472.
[13] Savale L, Guimas M, Ebstein N, et al. Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol, 2020,73:130-139.
[14] Deroo R, Trépo E, Holvoet T, et al. Vasomodulators and liver transplantation for portopulmonary hypertension: evidence from a systematic review and meta-analysis. Hepatology, 2020,72:1701-1716.
[15] Sadd CJ, Osman F, Li Z, et al. Long-term outcomes and survival in moderate-severe portopulmonary hypertension after liver transplant. Transplantation, 2021,105:346-353.
[16] 中华医学会心血管病学分会肺血管病学组, 中华心血管病杂志编辑委员会. 中国肺高血压诊断和治疗指南2018. 中华心血管病杂志, 2018,46:933-964. |
